Precision medicine and Treat-to-Target approach in atopic dermatitis: enhancing personalized care and outcomes.

BACKGROUND

Atopic Dermatitis (AD) is a chronic inflammatory skin disease affecting a significant portion of the global population. While conventional treatments effectively control and manage symptoms, there is a growing need for more personalized and precise approaches for patients. Precision medicine has emerged as a promising therapeutic strategy that tailors treatment to the individual characteristics of each patient. Complementing this, the Treat-to-Target (T2T) strategy sets specific clinical goals and involves continuous monitoring and treatment adjustments based on real-time patient responses and biomarker data.

OBJECTIVES

This review aims to explore the latest advancements in precision medicine and the T2T strategy for AD.

METHODS

A comprehensive literature review was conducted to identify the most recent studies and advancements in precision medicine and the T2T strategy for AD.

RESULTS

Recent studies highlight the effectiveness of precision medicine in achieving sustained remission and improving the quality of life for patients. The T2T strategy was shown to be effective in preventing exacerbations and adapting treatments based on real-time patient responses and biomarker data.

STUDY LIMITATIONS

The lack of a consensus on the clinical implementation of precision medicine and T2T, limited longitudinal studies validating long-term outcomes, challenges in stratifying patients due to biomarker heterogeneity, and barriers to integrating emerging diagnostic technologies into routine practice.

CONCLUSIONS

Precision medicine and the T2T strategy represent significant advancements in the management of AD. These approaches offer the potential for more personalized, effective, and adaptive treatment protocols, leading to improved patient outcomes. Continuous research and development in these areas are essential to fully realize their potential and integrate them into routine clinical practice.